IQVIA Gears Up to Report Q3 Earnings: Here's What You Should Know
Werte in diesem Artikel
IQVIA Holdings, Inc. IQV is scheduled to release its third-quarter 2024 results on Oct. 31, before market open.See Zacks Earnings Calendar to stay ahead of market-making news.IQVIA Holdings Inc. Price and EPS Surprise IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. QuoteIQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%.IQVIA’s Q3 ExpectationsThe Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.1% growth from the year-ago quarter’s actual. The top line is likely to have been driven by increased revenues across the Technology and Analytics segment (TAS), and Research and Development segments (RD&S).Our estimate for revenues from TAS is pegged at $1.5 billion, suggesting a 4.9% gain on a year-over-year basis. This segment’s revenue growth is expected to be fueled by improvements in Consulting and Analytics. The launch of a GenAI solution, which collects structured and unstructured survey inputs from more than 30,000 healthcare professionals across 36 countries in multiple languages and delivers analytics and insights to its clients, is likely to have benefited this segment.The RD&S revenues are expected to be $2.2 billion, hinting at a 2.4% rise from the year-ago reported figure.Revenues in this segment are anticipated to be driven by the strength across VRSK’s oncology department.Our estimate for Contract sales and Medical solutions’ (CSMS) revenues is pegged at $182.9 million, implying a marginal decline from the year-ago quarter’s actual.The consensus estimate for earnings per share is pegged at $2.8, suggesting 12.9% year-over-year growth. The bottom line is expected to have been driven by revenue growth and cost management discipline.Our estimate for the third quarter’s adjusted EBITDA is pegged at $938.6 million, suggesting 5.7% year-over-year growth.What Our Model Says About IQVOur proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.IQV has an Earnings ESP of -0.54% and a Zacks Rank of 3 at present.Stocks to ConsiderHere are a few stocks from the broader Business Services sector, which, according to our model, have the right combination of elements to beat on earnings this time around.Mastercard MA: The Zacks Consensus Estimate for the company’s third-quarter 2024 revenues is pegged at $7.3 billion, suggesting growth of 11% from the year-ago quarter. For earnings, the consensus mark is pegged at $3.7 per share, indicating a 10% year-over-year rise. MA beat the consensus estimate in the past four quarters. It has an earnings surprise of 3.5%, on average.MA has an Earnings ESP of +0.44% and a Zacks Rank of 2 at present. It is scheduled to declare its third-quarter 2024 results on Oct. 30.You can see the complete list of today’s Zacks #1 Rank stocks here.Visa V: The Zacks Consensus Estimate for third-quarter 2024 revenues is pegged at $9.5 billion, indicating an increase of 10.2% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at $2.6 per share, indicating a 10.7% increase from the year-ago quarter’s actual. V beat the consensus estimate in the past four quarters, the earnings surprise being 2.9%, on average.V has an Earnings ESP of +0.05% and a Zacks Rank of 3 at present. It is scheduled to declare its third-quarter 2024 results on Oct. 29.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf IQVIA
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf IQVIA
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu IQVIA Holdings Inc Registered Shs
Analysen zu IQVIA Holdings Inc Registered Shs
Datum | Rating | Analyst | |
---|---|---|---|
09.10.2018 | IQVIA Buy | UBS AG | |
02.10.2018 | IQVIA Outperform | Robert W. Baird & Co. Incorporated | |
25.07.2018 | IQVIA Buy | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
09.10.2018 | IQVIA Buy | UBS AG | |
02.10.2018 | IQVIA Outperform | Robert W. Baird & Co. Incorporated | |
25.07.2018 | IQVIA Buy | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für IQVIA Holdings Inc Registered Shs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen